The company announced the 16-year mid-year report: the first half of the year achieved revenue of 1.676 billion yuan, an increase of 25.82%; the net profit attributable to the company reached 377 million yuan, an increase of 31.04%, and the net profit after deduction was 371 million yuan, an increase of 35.40%. In line with expectations.

The company also announced a number of joint stock mergers and acquisitions:

(1) Funding of 106 million yuan to further acquire the 17.59% equity of Eucalyptus, with a total shareholding of 37.59%, achieving relative control.

(2) Lepu Pharmaceutical invested RMB 150 million to acquire and increase capital of Beijing Yongzheng Pharmaceutical, holding 75% equity.

(3) Lepu Pharmaceutical invested RMB 90 million to invest in 60% equity of Xinxiang Hengjiuyuan Pharmaceutical.

(4) Invested and acquired RMB 107 million to acquire and increase capital Anhui Anhui High-tech Cardiovascular Hospital and Kangyuan Cardiovascular Disease Research Institute.

(5) Invested 70.7 million yuan to acquire and increase capital 20.20% equity of Beijing Kushur.

Peaceful point of view:

Medical and pharmaceutical products have promoted rapid development of performance: the medical machinery sector achieved revenue of 1.04 billion yuan, a year-on-year increase of 25.04%, and a net profit of 313 million yuan. Its stent system achieved a revenue of 503 million yuan, a year-on-year increase of 15.99%. In the second half of last year, surgical instruments such as staplers were added to achieve 0.58 billion yuan. In the IVD field, the products of the laboratory were in parallel with the POCT, achieving a revenue of 102 million yuan, a year-on-year increase of 143.72%. Products such as occluders and pacemakers maintained a steady growth trend. The pharmaceutical sector realized revenue of 551 million yuan, a year-on-year increase of 26.16%, and a net profit of 149 million yuan, an increase of 81.11%. Among them, Lepu Pharmaceutical achieved a revenue of 252 million yuan with the support of the heavy variety clopidogrel, an increase of 118.62% over the same period. Xindonggang's key development of the formulation business has achieved initial results, achieving 288 million yuan in revenue, an increase of 105.52% over the same period. At the same time, the company further expanded its variety and made the antihypertensive drug losartan potassium hydrochlorothiazide tablets (Mihua Pharmaceutical), amlodipine besylate tablets (Yongzheng Pharmaceutical), and valsartan capsules (Hengjiu Pharmaceutical) Orientation cardiovascular drug supply platform.

Sanger Sequecing Instrument

Sanger Sequencing, which was used for DNA nucleotide sequencing, was created and rewarded Nobel Prize by Frederick Sanger in 1977.
How does the Sanger Sequencing work?
Firstly, we use the primer to have a short primer binding next to the region of interest on the DNA template. Then, the DNA polymerase starts building up from the primer by adding complementary nucleotides to the DNA strand.
To find the STOP that allows us to identify the base of the very end of the particular DNA fragment. Sanger sequencing principle is applied to removing an oxygen atom from the ribonucleotide. ddNTP (Dideoxynucleotide) is to put a wrench into a gear. The polymerase enzyme will no longer add normal nucleotides to this DNA chain. The extension would stop.
We can identify the Chain terminating nucleotide by a specific fluorescent dye. Superyears Genetic Analyzer can support fluorescent dye up to 6/8 colors to be exact.
Sanger sequencing results in the formation of extension products of various lengths terminated with dideoxynucleotides at the 3' end.
Capillary Electrophoresis separates the extension products.
An electrical current injects the molecules into a long capillary tube filled with a gel polymer.
During CE (Capillary Electrophoresis), negatively charged DNA fragments move forward to the Positive electrode.
The speed at which a DNA fragment migrates through the medium is inversely proportional to its molecular weight.
This process can separate the extension products by size at a resolution of one base.
A laser excites the dye-labeled DNA fragments as they pass through a tiny window at the end of the capillary.
The excited dye emits light at a characteristic wavelength that is detected by a light sensor.
The software can interpret the detected signal and translate it into a basecall.
A sequencing reaction is performed in the presence of all four terminated nucleotides, a pool of DNA fragments that are measured and separated base by base.
Data file showing the sequence of the DNA in a colorful electropherogram.

Based on the Sanger sequencing principle, the gene analyzer produced by Superyears Gene can be used for gene sequence analysis and fragment analysis, which can quickly detect multi-target (10-70 loci) genes at a time. The Genetic Analyzer has the advantages of low single detection cost, simple operation, and intuitive and straightforward result interpretation. It is a powerful tool for medium-throughput and multi-gene joint inspection.

Superyears focus on developing a genetic instrument that brings the best testing results. We can partner with you to create better solutions with our ongoing efforts and innovation that support laboratory productivity. Superyears gene company can provide high-quality and value-added products that can generate excellent outcomes from lab testing. Including DNA extractor for samples collection, Real-time PCR for samples amplification, compatible reagents within the use of multiple mainstream instruments, state-of-art genetic testing analyzer, and self-sufficient analyzing software.

Sanger Sequecing Instrument,Genetic Analyzer Forensic Dna Instrument,Sanger Sequecing Dna Analyzer,Sanger Sequencing Method

Nanjing Superyears Gene Technology Co., Ltd. , https://www.superyearsglobal.com